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ABSTRACT Severe fever with thrombocytopenia syndrome (SFTS) is an emerging

tick-borne disease endemic in parts of Asia. The etiologic agent, SFTS virus (SFTSV;
family Bunyaviridae, genus Phlebovirus) has caused signiﬁcant morbidity and mortality in China, South Korea, and Japan, with key features of disease being intense fever, thrombocytopenia, and leukopenia. Case fatality rates are estimated to be in the
30% range, and no antivirals or vaccines are approved for use for treatment and
prevention of SFTS. There is evidence that in human cells, SFTSV sequesters STAT
proteins in replication complexes, thereby inhibiting type I interferon signaling. Here,
we demonstrate that hamsters devoid of functional STAT2 are highly susceptible to
as few as 10 PFU of SFTSV, with animals generally succumbing within 5 to 6 days after subcutaneous challenge. The disease included marked thrombocytopenia and inﬂammatory disease characteristic of the condition in humans. Infectious virus titers
were present in the blood and most tissues 3 days after virus challenge, and severe
inﬂammatory lesions were found in the spleen and liver samples of SFTSV-infected
hamsters. We also show that SFTSV infection in STAT2 knockout (KO) hamsters is responsive to favipiravir treatment, which protected all animals from lethal disease
and reduced serum and tissue viral loads by 3 to 6 orders of magnitude. Taken together, our results provide additional insights into the pathogenesis of SFTSV infection and support the use of the newly described STAT2 KO hamster model for evaluation of promising antiviral therapies.
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IMPORTANCE Severe fever with thrombocytopenia syndrome (SFTS) is an emerging

viral disease for which there are currently no therapeutic options or available vaccines. The causative agent, SFTS virus (SFTSV), is present in China, South Korea, and
Japan, and infections requiring medical attention result in death in as many as 30%
of the cases. Here, we describe a novel model of SFTS in hamsters genetically engineered to be deﬁcient in a protein that helps protect humans and animals against
viral infections. These hamsters were found to be susceptible to SFTSV and share
disease features associated with the disease in humans. Importantly, we also show
that SFTSV infection in hamsters can be effectively treated with a broad-spectrum
antiviral drug approved for use in Japan. Our ﬁndings suggest that the new SFTS
model will be an excellent resource to better understand SFTSV infection and disease as well as a valuable tool for evaluating promising antiviral drugs.
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evere fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne phlebovirus (family Bunyaviridae) that has recently emerged in parts of Asia and causes a
hemorrhagic disease syndrome with the cardinal features being thrombocytopenia and
leukopenia (1). Clinical presentation typically includes abrupt onset of fever with
headache, myalgia, lethargy, and diarrhea (2). Primarily affecting China, South Korea,
and Japan, mortality associated with SFTSV infection can be high, with case fatality rate
estimates reaching 30%. There is currently no antiviral therapy approved for the
treatment of severe fever with thrombocytopenia syndrome, and there are no vaccines
available to prevent the disease.
SFTSV is an enveloped virus with a trisegmented single-stranded RNA genome
consisting of a large (L) segment, a medium (M) segment, and a small (S) segment
(reviewed in reference 2). The L segment encodes the viral RNA-dependent RNA
polymerase required for genome replication and transcription. The M segment contains
the envelope glycoprotein, which in addition to mediating host cell entry, facilitates
virion assembly and maturation. Using an ambisense coding strategy, the S segment
encodes the nucleoprotein and a nonstructural protein (NSs). The nucleoprotein is a
multifunctional protein that protects the viral genome, is involved in the replication/
transcription process, and has a role in virion assembly (3, 4). The NSs protein of SFTSV
has been shown to inhibit the type I interferon (IFN) response through sequestration of
STAT proteins and other factors in viral replication complexes (5–7). Within the pathogenic phleboviruses, the NSs protein is considered the major virulence factor, playing
a central role in the disruption of the innate immune response to infection by targeting
the IFN antiviral response pathway (8).
Immunocompetent mice and golden Syrian hamsters have been shown to be
refractory to severe infection and disease following SFTSV challenge; however, mice
lacking IFN-␣/␤ receptors are highly susceptible and generally succumb from an acute
disease course (9–11). In the present study, we demonstrate an essential role for STAT2
in the control of SFTSV infection in hamsters and subsequently characterize the
pathogenesis and natural history of disease in hamsters deﬁcient in STAT2 signaling.
We also show that favipiravir, a broadly active antiviral drug approved for human use
in Japan, completely protects STAT2 knockout (KO) hamsters from lethal SFTSV challenge. The new hamster model of SFTS shares features of the human disease, including
hemorrhagic disease pathology and thrombocytopenia, and will further support antiviral drug and vaccine development efforts.
RESULTS
Susceptibility of STAT2 KO hamsters to SFTSV. Wild-type Syrian hamsters are
refractory to disease following SFTSV challenge (10). To investigate whether STAT2
deﬁciency would render hamsters susceptible to SFTSV, STAT2 KO hamsters were
inoculated subcutaneously (s.c.) with serial dilutions of SFTSV (10, 1, or 0.1 PFU) or sham
infected and observed for signs of illness. A dose of 10 PFU resulted in uniform lethality,
with all 4 animals succumbing by day 6 postinfection (p.i.) (Fig. 1A). With the 1-PFU
SFTSV challenge, only 1 of the 4 animals survived. There was no mortality observed at
a challenge dose of 0.1 PFU (Fig. 1A) or in sham-infected animals (data not shown). All
the hamsters challenged with 10 PFU started losing weight by day 3 p.i. (Fig. 1B), and
the weight loss coincided with the onset of lethargy in several animals. Animals
challenged with 1 PFU had slightly lower weight loss than the animals infected with 10
PFU, and the surviving hamster recovered slowly, as reﬂected by its modest weight gain
curve compared to those of the animals that were infected with 0.1 PFU. The 0.1-PFUand sham-infected animals did not show any signs of illness and steadily gained weight
at a higher trajectory throughout the study than the animals in the other groups (Fig.
1B). Based on the survival results, the 50% and 90% lethal doses (LD50 and LD90,
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FIG 1 Titration of SFTSV in STAT2 KO hamsters. Groups of 4 hamsters were infected by s.c. injection with
the indicated PFU of virus. (A) Survival; (B) daily percent changes and standard deviations in the mean
weights of surviving animals relative to the day of virus challenge.

respectively) of the HB29 strain of SFTSV in STAT2 KO hamsters by the s.c. challenge
route are approximately 0.5 and 4.6 PFU, respectively.
Hamsters heterozygous for the STAT2 KO are resistant to lethal SFTSV challenge. To further investigate the role of STAT2 in the control of SFTSV infection,
challenges of STAT2 KO hamsters and heterozygous littermates with a functional STAT2
allele were conducted in parallel. As expected, all of the homozygous STAT2 KO
hamsters succumbed to the 100-PFU SFTSV challenge dose by day 5 p.i., with notable
weight loss and slightly reduced activity beginning on day 3 (Fig. 2). In contrast, the
heterozygous animals showed no signs of illness, suggesting that a single functional
copy of the STAT2 gene is sufﬁcient to effectively control SFTSV infection and prevent
disease and mortality.
Pathogenesis of SFTSV in homozygous STAT2 KO hamsters. To gain insights into
the pathogenesis of SFTSV infection, a natural history of disease study was designed to
investigate several virologic, clinical, and laboratory parameters during the acute
infection in Syrian STAT2 KO hamsters. A challenge dose of 50 PFU of SFTSV was chosen
to ensure uniform lethality at 100 LD50. SFTSV-infected animals began losing weight on
day 3 p.i. (Fig. 3A). By day 4, the remaining infected hamsters had various degrees of
lethargy. On the morning of day 5, 1 of the 3 animals was found in a moribund state
and the other 2 hamsters had expired.
Serum and tissues were analyzed for the presence of infectious virus during the
course of the SFTSV infection. As shown in Fig. 3B, viremia and tissue viral titers were
not detectable until day 3 p.i. and were substantial in all tissues, with the exception of
the small intestine, by day 4. An amount of ⬎107 50% cell culture infectious dose
(CCID50)/ml serum or gram of tissue (including the small intestine) was found in the
moribund animal sacriﬁced on day 5 p.i. (Fig. 3B).
Hematologic analysis showed that erythrocyte parameters were largely unaffected
by the SFTSV infection with the exception of percent red blood cell (RBC) distribution
width (RDW%), which was signiﬁcantly increased 4 days p.i. (Table 1). In contrast, a
signiﬁcant decrease in platelets was observed starting on day 3 p.i., with the day 5
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FIG 2 Lethality of SFTSV infection in STAT2 KO homozygous and heterozygous hamsters. Animals
homozygous (n ⫽ 6) and heterozygous (n ⫽ 6) for the STAT2 KO were infected s.c. with 100 PFU of SFTSV.
(A) Survival; (B) daily percent changes and standard deviations in the mean weights of surviving animals
relative to the day of virus challenge. Sham-infected controls (n ⫽ 2) consisted of 1 homozygous animal
and 1 heterozygous animal.

hamster having critically low levels (Fig. 4A). Notably, similar amounts of platelet
clumps were observed in blood smears across all groups, including the sham-infected
control animals, so the reported values are likely an underestimate of the total platelet
concentration. To assess whether the thrombocytopenia was due to reduced production of platelets, bone marrow smears were also examined and determined to have no
deﬁcits in megakaryocytes (not shown). White blood cell (WBC) counts were estimated
by visual analysis of blood smears prepared immediately after blood collection in the
biosafety level 3 (BSL-3) laboratory. WBC counts did not differ signiﬁcantly from those
of the sham-infected controls (Table 1). A shift toward increased percentages of
neutrophils and decreasing percentages lymphocytes was observed as the SFTSV
infection progressed in the hamsters (Fig. 4B and C). This inversion of neutrophil to
lymphocyte numbers is indicative of a strong inﬂammatory response (12). Also consistent with inﬂammation, immature (band) neutrophils were elevated in 2 of 3 animals on
day 4 and in the moribund animal on day 5 (Fig. 4D).
The blood smears were assessed for toxic changes in neutrophils to gain further
insights into the inﬂammatory response during the acute SFTSV infection. Toxic
changes are cytoplasmic details (basophilia, vacuolation, Dohle bodies, and granulation) that occur while neutrophils are formed in the bone marrow under a signiﬁcant
cytokine inﬂuence (13). The toxic changes were graded on a scale of 0 to 3 with 0 being
no toxic changes and 3 being marked toxic changes. As shown in Fig. 4E, toxic changes
indicative of a vigorous systemic inﬂammatory response became pronounced in one of
the day 3 group hamsters and all animals by day 4 p.i.
Serum obtained from each animal at the time of sacriﬁce was also used for a
comprehensive analysis of serum biochemistry parameters (Table 2). Most notably,
alkaline phosphatase (ALP) and cholesterol (CHOL) levels began to increase by day 3 p.i.
and were found to be signiﬁcantly elevated in the animals sacriﬁced on day 4. The
moribund day 5 animal had dramatically higher concentrations of ALP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT),
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and total bilirubin (TBIL) than the sham-infected controls. There was also a trend toward
decreasing concentrations of glucose (GLU) and albumin (ALB) starting 3 to 4 days p.i.
with a marked reduction in the day 5 hamster. The day 5 animal and one of the day 4
animals had markedly elevated BUN concentrations.

TABLE 1 Hematology analysis during the course of the SFTSV infection in STAT2 KO Syrian golden hamstersa
Hematology
parameter
(unit)
RBC (106/l)
HGB (g/dl)
HCT (%)
MCV (ﬂ)
MCHC (g/dl)
RDW (%)
PLT (103/l)
MPV (ﬂ)
WBC (103/l)
% Bands
% Neut
% Lymph
% Mono
% Eos

Group mean value ⴞ SD for infected hamsters on:
Day 1
8.4 ⫾ 0.2
18.7 ⫾ 0.9
55.1 ⫾ 2.4
65.7 ⴞ 1.7*
34.0 ⫾ 0.4
18.7 ⫾ 0.3
652.7 ⫾ 128.6
6.9 ⫾ 0.1
4.3 ⫾ 1.3
0.7 ⫾ 0.6
49.0 ⫾ 9.2
46.0 ⫾ 11.4
2.0 ⫾ 1.0
2.3 ⫾ 1.5

Day 2
8.2 ⫾ 0.2
18.4 ⫾ 0.6
51.3 ⫾ 0.5
62.4 ⫾ 1.0
35.8 ⫾ 0.7
18.5 ⫾ 0.2
622.0 ⫾ 66.1
7.2 ⫾ 0.2
5.9 ⫾ 3.9
1.0 ⫾ 1.0
64.7 ⫾ 17.2
31.7 ⫾ 16.7
1.3 ⫾ 0.6
1.3 ⫾ 1.5

Day 3
8.1 ⫾ 0.6
18.2 ⫾ 1.2
52.1 ⫾ 2.8
64.0 ⫾ 1.4
35.0 ⫾ 0.6
19.1 ⫾ 0.4
332.7 ⴞ 152.0*
7.4 ⫾ 1.6
8.3 ⫾ 7.4
0.7 ⫾ 0.6
64.3 ⫾ 14.4
24.7 ⴞ 11.7*
10.0 ⴞ 2.6**
0.3 ⫾ 0.6

Day 4
8.0 ⫾ 1.3
17.2 ⫾ 2.5
48.2 ⫾ 6.9
60.0 ⫾ 1.2
35.7 ⫾ 0.1
19.8 ⴞ 0.5*
284.0 ⴞ 45.7*
7.6 ⫾ 1.3
4.8 ⫾ 2.4
3.7 ⫾ 3.1
68.3 ⴞ 1.2*
21.0 ⴞ 2.6*
5.7 ⫾ 6.0
1.3 ⫾ 0.6

Day 5
6.9
13.5
42.6
62.1
31.6
21.7
92.0
6.6
3.2
7.0
70.0
17.0
6.0
0.0

Normal
value ⴞ SD
9.0 ⫾ 0.6
19.4 ⫾ 1.2
55.7 ⫾ 2.3
62.2 ⫾ 1.6
34.9 ⫾ 1.0
18.8 ⫾ 0.4
605.5 ⫾ 138.2
6.6 ⫾ 0.5
5.3 ⫾ 1.2
0.5 ⫾ 1.0
39.8 ⫾ 14.7
55.8 ⫾ 14.9
3.0 ⫾ 2.6
1.8 ⫾ 1.0

animals were sacriﬁced daily on days 1 to 4 p.i. (n ⫽ 3). Two animals in the day 5 group succumbed to the infection prior to time of sacriﬁce; therefore, data
for only one animal are shown for day 5. *, P ⬍ 0.05; **, P ⬍ 0.01 compared to sham-infected controls (n ⫽ 4). Statistically signiﬁcant differences are in boldface.
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FIG 3 Temporal analysis of weight change and viral burden during the course of SFTSV infection in STAT2
KO hamsters. Animals (n ⫽ 3/day) were infected s.c. with 50 PFU of SFTSV and sacriﬁced on the indicated
day for analysis of viral titers. (A) Daily percent changes and standard deviations in the mean weights of
surviving animals relative to the day of virus challenge; (B) serum and tissue viral titers. Two animals in
the day 5 group succumbed to the infection prior to time of sacriﬁce; therefore, data for only one animal
are shown for day 5.

Gowen et al.

Journal of Virology

Downloaded from http://jvi.asm.org/ on February 15, 2017 by UTAH STATE UNIV

FIG 4 Alteration of hematologic parameters during the course of SFTSV infection in STAT2 KO hamsters.
Groups of hamsters were challenged as described for Fig. 3. Changes in platelets (A), percent neutrophils
(B), percent lymphocytes (C), and percent band neutrophils (D) and neutrophil toxic change scores (E) are
shown. Unique symbols in each treatment group represent values for the same animal across all parameters. Data for 4 sham-infected, healthy control animals are included for comparison. *, P ⬍ 0.05 compared
to sham-infected controls.

Histologically, lesions were observed in the liver and spleen, with other tissues not
having microscopic changes (Fig. 5). The liver lesions consisted of multifocal periportal
and random, acute, neutrophilic hepatitis (Fig. 5A). Splenic lesions consisted of multifocal acute neutrophilic splenitis focused mostly on the white pulp with lymphoid
necrosis (Fig. 5B). Liver lesions were initially observed in hamsters starting 3 days p.i.,
while splenic lesions were seen as early as day 2 in two animals (Fig. 5E).
Favipiravir provides complete protection from lethal SFTSV infection in hamsters. Having characterized SFTSV infection in STAT2 KO hamsters, we designed an
experiment to evaluate two broad-spectrum antiviral drugs in the newly developed
disease model. High and intermediate doses of favipiravir (300 mg/kg of body weight/
February 2017 Volume 91 Issue 3 e01942-16
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TABLE 2 Blood chemistry parameters during the course of the SFTSV infection in STAT2 KO Syrian golden hamstersa
Group mean value ⴞ SD for infected hamsters on:
Day 1
146.3 ⫾ 9.2
95.7 ⫾ 22.6
81.3 ⫾ 3.1
23.0 ⫾ 5.8
ⱕ0.2
231.7 ⫾ 59.0
6.2 ⫾ 0.2
0.2
3.1 ⫾ 0.1
9.8 ⫾ 0.8
15.2 ⫾ 0.5
164.3 ⫾ 2.3
10.3 ⫾ 0.6
90.3 ⫾ 23.5
⬎2,500
5.3 ⫾ 0.2
408.3 ⫾ 100.4
143.7 ⫾ 2.1
8.8 ⫾ 0.2
94.0 ⫾ 3.6

Day 2
137.7 ⫾ 9.3
108.3 ⫾ 19.3
76.7 ⫾ 8.5
20.9 ⫾ 4.4
⬍0.2
257.3 ⫾ 27.2
6.3 ⫾ 0.3
0.1
3.2 ⫾ 0.2
8.8 ⫾ 0.3
15.3 ⫾ 0.3
163.0 ⫾ 25.1
⬍10.0
63.3 ⫾ 49.7
⬎2,500
5.0 ⫾ 0.6
338.7 ⫾ 29.7
141.7 ⫾ 1.5
8.8 ⫾ 0.5
93.7 ⫾ 4.0

Day 3
199.3 ⫾ 37.6
85.0 ⫾ 44.0
115.7 ⫾ 49.7
14.2 ⫾ 2.4
ⱕ0.2
204.0 ⫾ 78.9
6.3 ⫾ 0.6
0.1
2.9 ⫾ 0.3
9.1 ⫾ 1.3
14.2 ⫾ 1.1
227.7 ⫾ 42.4
11.0 ⫾ 1.0
92.7 ⫾ 25.8
2,412 ⫾ 153
5.5 ⫾ 0.4
297.7 ⫾ 42.2
139.7 ⫾ 1.2
9.5 ⫾ 1.5
93.3 ⫾ 2.9

Day 4
399.7 ⴞ 50.6***
75.3 ⫾ 47.9
84.3 ⫾ 26.0
30.4 ⫾ 16.5
0.3 ⫾ 0.1
131.3 ⫾ 52.0
6.2 ⫾ 0.6
0.1
2.6 ⫾ 0.1
10.4 ⫾ 1.1
13.5 ⫾ 0.4
269.0 ⴞ 69.9*
11.3 ⫾ 2.3
232.0 ⫾ 186.2
⬎2,500
5.4 ⫾ 0.2
421.7 ⫾ 131.4
142.0 ⫾ 1.0
8.4 ⫾ 1.3
96.0 ⫾ 4.4

Day 5
⬎993.0
⬎1,000
⬎1,000
91.5
0.6
19.0
4.6
3.3
2.0
45.0
10.1
217.0
19.0
105.0
1,525
6.1
⬎500.0
140.0
8.3
93.0

Normal mean
value ⴞ SD
140.8 ⫾ 15.9
137.0 ⫾ 85.0
126.0 ⫾ 55.5
20.8 ⫾ 2.2
ⱕ0.2
268.0 ⫾ 80.0
5.8 ⫾ 0.2
0.2 ⫾ 0.1
2.9 ⫾ 0.2
10.6 ⫾ 1.2
14.5 ⫾ 0.4
168.8 ⫾ 34.9
10.3 ⫾ 0.5
115.3 ⫾ 38.9
⬎2,500
4.7 ⫾ 1.0
360.0 ⫾ 117.9
141.0 ⫾ 1.6
10.0 ⫾ 0.3
93.3 ⫾ 4.4

animals were sacriﬁced daily on days 1 to 4 p.i. (n ⫽ 3). Two animals in the day 5 group succumbed to the infection prior to time of sacriﬁce; therefore, data
for only one animal are shown for day 5. *, P ⬍ 0.05; ***, P ⬍ 0.001 compared to sham-infected controls (n ⫽ 4). Statistically signiﬁcant differences are in boldface.

aThree

day and 150 mg/kg/day) and a single dose of ribavirin (75 mg/kg/day) were tested. As
shown in Fig. 6A, treatment with either dose of T-705 provided complete protection
against a lethal SFTSV challenge. In contrast, none of the animals receiving ribavirin
therapy survived the infection, although there appeared to be a slight delay in time of
death. As expected, all the animals in the placebo group succumbed to infection by day
5 p.i.
Hamster weights were also tracked during the course of the efﬁcacy study (Fig. 6B).
The weight change data are indicative of illness in both of the favipiravir treatment
groups and is consistent with the reduced activity that was observed mostly 5 to 10
days p.i. in these treatment groups. A dose-dependent effect was evident as the
300-mg/kg/day favipiravir group lost less weight and began to recover earlier than the
animals receiving 150 mg/kg/day favipiravir. The rapid weight loss in the ribavirintreated animals is consistent with the survival data.
The effect of treatments on reducing day 4 viral titers was evaluated in subsets of
hamsters infected and treated in parallel to those observed for mortality (Fig. 6C). In a
dose-responsive manner, animals treated with favipiravir showed signiﬁcant reductions
in viremia levels in serum and all four tissues compared to the placebo- and ribavirintreated groups. Notably, in the high-dose favipiravir treatment group, there was no
detectable virus found in the liver or lung tissues of one of the hamsters and a second
animal had no detectable virus in the liver, kidney, or lung tissues. Due to the severity
of the SFTSV infection, one hamster in the placebo group succumbed to the infection
prior to the time of sacriﬁce and therefore could not be included in the analysis.
Moreover, sufﬁcient amounts of serum could not be obtained from the other two
placebo animals because they were moribund at the time of sacriﬁce.
DISCUSSION
Previous SFTSV studies in mice have demonstrated the importance of the type I IFN
response in preventing severe disease in mice (10). Further, recent studies using human
cells have shown that STAT2 is speciﬁcally targeted and sequestered by the NSs protein
of SFTSV during infection as a mechanism for blocking the initiation of the type I IFN
response program (5). Based on these ﬁndings, we hypothesized that hamsters deﬁcient in STAT2 would be susceptible to SFTSV infection and lethal disease. In the
present report, we describe a new SFTS disease model in a second species by showing
February 2017 Volume 91 Issue 3 e01942-16
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Blood chemistry
parameter (unit)
ALP (U/liter)
ALT (U/liter)
AST (U/liter)
BUN (mg/dl)
CREA (mg/dl)
GLU (mg/dl)
TP (mg/dl)
TBIL (mg/dl)
ALB (g/dl)
PHOS (mg/dl)
Ca (mg/dl)
CHOL (mg/dl)
GGT (U/liter)
LIP (U/liter)
AMY (U/liter)
Mg (mg/dl)
TRIG (mg/dl)
Na⫹ (mEq/liter)
K⫹ (mEq/liter)
Cl⫺ (mEq/liter)
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FIG 5 Histopathologic lesions observed from the SFTSV infection in STAT2 KO hamsters. (A to D)
Representative sections of liver (arrow marking neutrophilic hepatitis) (A) and spleen (white pulp, arrow
marking severe neutrophilic splenitis) (B) from an infected animal on day 4 p.i. and sections of liver (C)
and spleen (white pulp) (D) from a sham-infected control animal. Bar (lower right corner of each panel),
50 m. Hematoxylin and eosin stain; magniﬁcation, ⫻400. (E) Summary of histopathology ﬁndings
represented as a heat map. Lesions were scored as follows: 0, no lesions; 1, minimal; 2, mild; 3, moderate;
4, severe.

that hamsters defective in STAT2 function are highly susceptible to severe infection
following challenge with as little as 10 PFU of SFTSV. No remarkable difference in
susceptibility associated with age or gender of the STAT2 KO hamsters was observed;
however, larger cohorts to increase statistical power for such comparisons would be
needed to better address this question. We also show that heterozygous littermates
that possess a functional copy of the STAT2 gene are completely refractory to infection,
indicating that the lower expression levels from a single allele are sufﬁcient to confer
protection. Although we did not investigate whether the NSs protein of SFTSV interacts
with and sequesters hamster STAT proteins into viral replication centers, our data
suggest that this is unlikely since hamsters expressing a functional STAT2 showed no
signs of disease.
Our ﬁndings on the natural history of SFTSV infection and disease in STAT2 KO
hamsters indicate that following a 50-PFU challenge by s.c. injection, infectious viral
loads reach detectable levels in the serum and most tissues in a proportion of the
animals between 48 and 72 h after infection. By day 4 of the infection, signiﬁcant viral
loads are present in all hamsters and visible signs of illness became apparent. Consistent with a cardinal feature of the human disease (2), SFTSV infection in hamsters
resulted in thrombocytopenia and the marked systemic inﬂammation that is common
February 2017 Volume 91 Issue 3 e01942-16
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FIG 6 Effects of favipiravir treatment on survival outcome, percent weight loss, and virus titers in STAT2 KO
hamsters challenged s.c. with SFTSV. Hamsters in each treatment group received the indicated doses of favipiravir,
ribavirin, or placebo (p.o., twice daily for 10 days) beginning 1 day p.i. (A) Percent survival (n ⫽ 5/group); (B) daily
percent changes and standard deviations in the mean weights of surviving animals relative to the day of virus
challenge; (C) viremia and tissue viral titers on day 4 p.i. (n ⫽ 3/group). One animal in the placebo group expired
prior to the time of sacriﬁce and was not included in the analysis. Also, sufﬁcient serum for viremia analysis could
not be obtained from the remaining 2 moribund animals in the placebo group. **, P ⬍ 0.01; ***, P ⬍ 0.001
compared to animals receiving placebo. a, P ⬍ 0.05; b, P ⬍ 0.01, compared to ribavirin-treated animals. Tx,
treatment.

in hemorrhagic fever of viral etiology (14). It is possible that the observed thrombocytopenia is due to the platelet consumption often seen to occur with viral hemorrhagic
fever and other coagulation disorders (15); however, we found no evidence of increased megakaryocyte production or viral cytopathic effects (CPE) in these cells.
Leukopenia, a common clinical laboratory ﬁnding associated with SFTS in humans (2),
was not evident in the infected hamsters.
The serum biochemistry ﬁndings were highly suggestive of liver disease. Elevations
in ALP, ALT, AST, GGT, and TBIL are an indication of liver pathology (16). Speciﬁcally, AST
and ALT indicate hepatocyte injury. Signiﬁcant muscle damage can also cause an
increase in AST, but since neutrophilic hepatitis was observed histologically, the
elevated AST was due to liver dysfunction. In addition, the elevated levels of ALP, GGT,
and TBIL were also the result of hepatocellular pathology as conﬁrmed by the histopathologic lesion of neutrophilic hepatitis. Other serum biochemistry data suggestive
of liver pathology were the downward trends in the levels of GLU and ALB, both
products synthesized by the liver. Also, starting on day 3 p.i., the infected hamsters
presented with increasing levels of CHOL, which may be secondary to cholestasis, a
reduction in bile ﬂow, suggesting hepatobiliary disease (16). The presence of cholestasis was also supported by the increases in ALP, GGT, and TBIL.
The moribund animal in the day 5 group and one of the hamsters in the day 4
group had very high BUN. The high BUN was likely due to dehydration and not renal
insufﬁciency, since urine speciﬁc gravity was adequately concentrated in the infected animals, as in sham-infected controls and no histologic lesions were present
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in kidney tissue collected from SFTSV-infected hamsters. The dramatic increase in
PHOS on day 5 p.i. also suggests a decreased glomerular ﬁltration rate secondary to
dehydration (16).
Histologically, lesions were found only in spleen and liver tissues. Histopathology
observed in the liver was consistent with the blood chemistry results and viral titer data,
with the animals that had the most severe lesions generally having high viral loads and
altered liver parameters consistent with liver dysfunction. Previous studies describing
histopathology associated with SFTSV infection in mice have reported differences in
tissues affected. Consistent with the study by Tani et al. using IFN-␣/␤ receptor
knockout (IFNAR⫺/⫺) on a C57BL/6 mouse background and the SPL010 strain of SFTSV
(9), we observed inﬂammatory lesions in the liver and the splenic lymphoid tissue.
However, the inﬂammatory reaction in the hamster model was strongly neutrophilic
compared to the mouse model. In contrast, we did not observe lymphoid necrosis in
the lymph nodes evaluated. Interestingly, the report by Liu and colleagues using
IFNAR⫺/⫺ mice on a different background (129/Sv) and with a different strain of SFTSV
(YL-1) detected SFTSV by immunohistochemistry in multiple organs, but no histologic
lesions were present (10). Collectively, the results from rodent studies support the idea
that type I IFN is essential but that host and virus factors, as well as challenge dose and
route, can alter disease development. Our ﬁndings suggest that the STAT2 KO hamsters
are succumbing from overwhelming severe acute systemic infection and inﬂammatory
response with the likely contribution of dehydration that ultimately leads to cardiovascular failure.
Finally, we also show the STAT2 KO hamster SFTSV infection model is a suitable
option to evaluate potential therapeutic treatments. The activity of favipiravir, a promising broad-spectrum antiviral with demonstrated activity against SFTSV infection in
mice (9) and other related phleboviral infections in rodents (17–19), was conﬁrmed. Of
note, in contrast to the report by Tani and coworkers in which signiﬁcant efﬁcacy was
observed with ribavirin at a dose of 25 mg/kg/day (9), we found the compound to be
ineffective against SFTSV in STAT2 KO hamsters at a dose of 75 mg/kg/day. The
difference in ribavirin efﬁcacy may be due to a number of factors, including dosing
frequency, treatment initiation time, and route of administration. Also, Tani et al. used
a different strain of SFTSV (SPL010) and challenged mice with ⬎10,000-fold more virus
than the amount inoculated into hamsters. Taken together, our data support the use of
the hamster SFTSV infection model to further explore the pathogenesis of SFTSV
infection and for early-stage antiviral drug development efforts.
MATERIALS AND METHODS
Ethics statement. All animal procedures complied with USDA guidelines and were conducted at the
AAALAC-accredited Laboratory Animal Research Center at Utah State University under protocol 2383,
approved by the Utah State University Institutional Animal Care and Use Committee.
Animals. The development of the STAT2 KO golden Syrian hamsters used has been previously
described (20). Male and female 6- to 7-week-old STAT2 KO hamsters were obtained from the breeding
colony at Utah State University (Logan, UT). The animals were fed autoclaved Harlan Lab Block and
sterilized tap water ad libitum and acclimated for approximately 1 week in the biosafety level 3 (BSL-3)
containment facility prior to virus challenge.
Virus. SFTSV strain HB29 was obtained from Robert Tesh (World Reference Center for Emerging
Viruses and Arboviruses, The University of Texas Medical Branch, Galveston). The virus stock (5.6 ⫻
106 PFU/ml; 1 passage in Vero E6 cells) used was derived from a clariﬁed cell culture lysate
preparation. Virus stock was diluted in sterile minimum essential medium (MEM) to achieve the
desired challenge concentrations. All procedures with infectious SFTSV were conducted in BSL-3
laboratories.
Susceptibility of STAT2 KO hamsters to SFTSV. STAT2 KO hamsters were weighed on the day of
infection and grouped by weight and gender to minimize differences across experimental groups (n ⫽
4 per virus challenge dose; n ⫽ 3 for the sham-infected control group) in an initial titration study. The
animals were inoculated by subcutaneous (s.c.) injection of 0.2 ml containing one of three serial dilutions
of SFTSV or sham infected with MEM. The hamsters were observed for 15 days for morbidity and
mortality following SFTSV challenge. Animals were weighed daily, and the percent weight changes of the
infected animals relative to their starting weights were reported.
A second experiment was conducted using hamsters heterozygous for the STAT2 deletion. In this
study, hamsters were challenged s.c. with 0.2 ml containing 100 PFU of SFTSV or sham infected with the
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same volume of MEM. Body weight was measured daily, and the animals were observed for 12 days for
morbidity and mortality associated with SFTSV infection.
Pathogenesis and natural history of SFTSV infection in STAT2 KO hamsters. STAT2 KO hamsters
were grouped to minimize gender and weight differences and challenged with 50 PFU of SFTSV or sham
infected. Predetermined groups of 3 animals per group were sacriﬁced on days 1 to 5 postinfection (p.i.).
Animals were weighed each day prior to sacriﬁce, and the data were reported as the mean weights of
the infected animals relative to their starting weights. Sham-infected control hamsters were sacriﬁced on
days 1, 3, and 5 p.i. Prior to sacriﬁce, whole blood was collected from anesthetized animals by
retro-orbital bleed directly into Sarstedt Microvette K3 EDTA-coated tubes to minimize clotting for
hematologic analysis. Following euthanasia, hamsters were exsanguinated by cardiac puncture and
serum was obtained for biochemistry and viral titer analyses. Urine was collected to determine urine
speciﬁc gravity. Anticoagulated blood and bone marrow smears were prepared for manual white blood
cell (WBC) counts and bone marrow cytologic evaluation. Tissue samples of spleen, liver, kidney, lung,
brain, small intestine, heart, and lymph nodes were collected for infectious virus titer determination and
histopathology.
Viral titer determination. Virus titers were assayed using an infectious cell culture assay as
previously described (21). Brieﬂy, tissue samples were homogenized in a ﬁxed volume of MEM, and the
homogenates and serum were serially diluted and added to triplicate wells of Vero E6 (African green
monkey kidney, clone E6) cell monolayers in 96-well microtiter plates. The viral cytopathic effect (CPE)
was determined 11 days after plating, and the 50% endpoints were calculated as described previously
(22). The lowest limit of detection (LLD) for serum samples was 1.67 log10 CCID50/ml. The LLD for tissues
was generally in the range of 2 to 3 log10 CCID50/g. In samples presenting with undetectable tissue virus
titers, a value representative of the LLD was assigned for statistical purposes.
Hematology. Blood smears were prepared with whole blood collected in tubes coated with K3
EDTA anticoagulant. The total WBC count was estimated, a manual differential cell count was
performed, and blood smears were evaluated for morphological features by a medical technologist
and a board-certiﬁed veterinary clinical pathologist. WBC estimates and the percentages of immature neutrophils (Bands), neutrophils (Neut), lymphocytes (Lymph), monocytes (Mono), and eosinophils (Eos) were determined. Morphological features of toxicity were evaluated, and samples were
assessed for platelet clumping.
For evaluation of erythrocyte parameters and platelets, 10% formalin was added to EDTAanticoagulated whole-blood samples at a 1:1 ratio to inactivate virus prior to transport to the Utah
Veterinary Diagnostic Lab (Logan, UT) for analysis in an automated complete blood count (CBC)
instrument (Advia 120 Hematology Analyzer; Siemens Healthcare Diagnostics Inc., Tarrytown, NY).
Platelet and erythrocyte parameters, including red blood cell (RBC) counts, hemoglobin (HGB),
hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration
(MCHC), and RBC distribution width (RDW) were determined. Several tests were performed to
conﬁrm that there were no signiﬁcant differences observed in platelet and erythrocyte parameters
when comparing the 10% formalin-treated to untreated ETDA-anticoagulated hamster whole blood.
Because of discrepancies between the manual differential WBC numbers and the automated cell
counts, we reported the manual counts since the smears were made from fresh blood samples not
treated with formalin.
Serum biochemistry. A comprehensive 18-parameter serum biochemistry panel was performed on
all serum samples to evaluate liver and kidney function as well as electrolyte and ﬂuid balance. Tests
within the panel included alkaline phosphatase (ALP), alanine aminotransferase (ALT), blood urea
nitrogen (BUN), creatinine (CREA), glucose (GLU), total protein (TP), total bilirubin (TBIL), albumin (ALB),
phosphate (PHOS), calcium (Ca), cholesterol (CHOL), gamma-glutamyl transferase (GGT), lipase (LIP),
amylase (AMY), magnesium (Mg), triglycerides (TRIG), aspartate aminotransferase (AST), and electrolytes
(Na⫹, K⫹, Cl⫺). These tests were performed using a DRI-CHEM 4000 analyzer following the manufacturer’s
speciﬁcations (Heska, Des Moines, IA).
Histopathology. Tissue samples of spleen, liver, kidney, lung, brain, small intestine, heart, and
submandibular lymph nodes were preserved in 10% neutral buffered formalin and sent to the Utah
Veterinary Diagnostic Laboratory (UVDL, Logan, UT) for histopathologic examination by a board-certiﬁed
veterinary pathologist. In tissues where lesions were present, severity was scored on a scale of 0 to 4 with
0 indicating no lesions and 4 indicating severe lesions.
Evaluation of favipiravir and ribavirin against SFTSV infection in hamsters. STAT2 KO hamsters
were weighed on the morning of the infection and grouped to minimize gender and weight differences
across the treatment groups. Hamsters (n ⫽ 8 for treatment and placebo groups, n ⫽ 4 for the
sham-infected group) were challenged with 50 PFU of SFTSV. Favipiravir (300 or 150 mg/kg/day) and
ribavirin (75 mg/kg/day) treatments were administered twice daily for 10 days by oral gavage (p.o.)
starting 1 day after challenge. Favipiravir (T-705) was obtained from the Toyama Chemical Co. (Toyama,
Japan), and ribavirin was from ICN Pharmaceuticals, Inc. (Costa Mesa, CA). Both compounds were
dissolved in 0.4% carboxymethylcellulose (CMC; Sigma-Aldrich, St. Louis, MO) prior to administration.
Predetermined subsets of 3 animals each were sacriﬁced on day 4 p.i. for analysis of serum, liver, spleen,
kidney, and lung viral titers. The remaining hamsters continued to receive treatment and were observed
21 days for morbidity and mortality.
Statistical analysis. The Mantel-Cox log rank test was used for analysis of Kaplan-Meier survival
curves. One-way analysis of variance (ANOVA) with a Tukey posttest to correct for multiple comparisons
was performed to compare differences in hematologic values, blood chemistry parameters, and viral
titers. All statistical evaluations were done using Prism (GraphPad Software, La Jolla, CA).
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